In 2003, the International Breast Cancer Study Group (IBCSG) initiated two impactful randomized phase 3 trials: the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), both enrolling premenopausal women with hormone-receptor-positive early breast cancer. Here, NR4A1 is linked to breast carcinoma.